Seymour Street Medical and Dental Centre, Ringwood is providing Covid-19 vaccination. Covid 19 Pfizer vaccine and AstraZeneca Covid-19 vaccine are now available in our clinic. Covid 19 Pfizer vaccines are available for people from 5 year old and above. People aged 60 years and above can receive the AstraZeneca Covid-19 vaccine. You will be required to book an appointment for Covid-19 vaccination clinic.

Please be sure you turn up for your appointment for Covid19 vaccination. As the vaccine comes in multidose vial, once it opened up, it can only lasted for 6 hours before it has to be discarded. Given the limited number of vaccines are available, it is crucial not to waste any of the vaccines.

You can have Covid 19 vaccination in other vaccination hub. You can call 1800 675 398 to book an appointment or book online on For more information, please visit the website.

ATAGI recommends Covid-19 vaccine by Pfizer (Cominarty) is preferred over AstraZenaca Covid-19 vaccine in adults aged under 60 years. This recommendation is based on the increasing potentially risk of thrombosis with trombocytopenia following AstraZeneca vaccine in those under 60 years. Covid-19 vaccine AstraZeneca can be used in adults aged under 60 years where the benefits are likely to outweigh the risks for that individual and the person made an informed decision based on understanding of the risks and benefits. People who have had the first dose of Covid-19 vaccine AstraZeneca without any serious adverse effects can be given second dose, including adults under 60 years. For more information, please visit ATAG website.

There is recent updates from ATAGI about Covid 19 vaccines. 

Contraindications to receiving AstraZeneca Covid 19 vaccination are:

  • a history of cerebral venous sinus thrombosis
  • a history of heparin-induced thrombocytopenia
  • a history of idiopathic splanhnic (mesenteric, portal and splenic) venous thrombosis
  • anti-phospholipid syndrome with thrombosis

It is also recommended that people should not receive a second dose of AstraZeneca if they have experienced:

  • anaphylaxis to a previous dose of the vaccine, or to an ingredient of the vaccine
  • thrombosis with thrombocytopenia occuring after the first dose
  • capillary leak syndrome
  • other serious adverse events attributed to the first dose

Cominarty is recommended for the second dose for people in these groups who have received a first dose of Covid 19 vaccine AstraZeneca.

Contraindications to Cominarty are:

  • anaphylaxis to a previous dose or to an ingredient
  • myocarditis and/or pericarditis attributed to a previous dose
  • any other serious adverse event attributed to a previous dose

Precautious to the use of both Comirnaty and Covid 19 vaccine AstraZeneca:

  • a history of generalised (non-anaphylactic) reaction to a prior dose or an ingredient
  • past anaphylaxis to medications/vaccines which may contain polyethylene glycol or polysorbate 80
  • a history of confirmed macrocytosis with recurrent anaphylaxis which requires treatment

Precautionary conditions specific to Comirnaty:

  • a past history of inflammatory cardiac illness eg. myocarditis, pericarditis, endocarditis, acute rheumatic fever, complex or severe congenital heart disease, acute decompensated heart failure
  • a history of cardiac transplant

People with these conditions can still receive Comirnaty, however consultation with a cardiologist is recommended prior to vaccination.

ATAGI recommends a third dose as part of the primary course in individuals who are severely immunocompromised and outlines immunocomprosing conditions and therapies which a third primary dose is recommended. This applies to everyone aged 12 years or over who fits the criteria. An mRNA vaccine (Pfizer or Moderna) is preferred to Vaxzevria (Astrazeneca) for the third dose, but Vaxzevria can be used under certain conditions. The recommended interval for the third dose is 2-6 months after the second dose of vaccine. A minimum interval of 4 weeks may be considered in exceptional circumstances (eg. anticipated intensification of immunosuppression; outbreaks).

Covid 19 vaccine booster program details are as below:

  • Pfizer is recommended as a single dose, no matter which vaccine was administered as the primary course (some provisions for use of AstraZenesca are outlined)
  • the booster dose can be administered from three months after completing the primary course
  • a booster is not currently recommended for people under 11 years of age
  • the booster dose can be co-administered with the influenza vaccine
  • severely immunocompromised patients aged 12 years or older who receive a third dose as part of their primary course, booster doses (that is, a fourth dose) are recommended at 4 months 

TGA approved Moderna Covid 19 vaccine for use as a booster dose in people aged 16 years and older. The recommendations includes that:

  • using the Moderna vaccine (50 μg) as a booster dose in people aged 16 years and older five months after completion of a primary course of a Covid 19 vaccine
  • the Moderna (50 μg) and Pfizer vaccines are equally acceptable as a booster vaccine, including for pregnant women
  • severely immunocompromised people who are receiving a third primary dose of the Moderna Covid 19 vaccine should receive a 100 μg dose, noting a booster dose of any Covid 19 vaccine is not yet recommended for this cohort

A fourth dose of a Covid 19 vaccine (preferred vaccine, Pfizer) is recommended four months after an initial booster dose for the following groups:

  • All over 65s
  • All residents of aged and disability care facilities, regardless of age
  • Those aged 12 and above with severe immunocompromise
  • Aboriginal and Torres Strait Islander people aged 50 and older

For people in those categories who had a confirmed Covid 19 infection after receiving a first booster dose, the follow up booster is recommended with a gap of four months after infection. Additional booster dose should not be given with a gap of less than three months from a previous booster dose or Covid 19 infection.

Co-administration of a Covid-19 vaccine with other vaccines is not routinely recommended. A mininum 7-day interval is advised between administration of a Covid 19 vaccine and any other vaccine, including influenza vaccine. This interval can be shortened (including to same day administration) in special circumstances.

For any patient who is intending to travel overseas, it is strongly recommended to have Covid 19 vaccination given the current pandemic affecting the whole world. 

ATAGI has released recommendations on the use of the Pfizer Covid 19 vaccine for use in children aged 5-11 years. The recommended dose for this age group is 19 μg (0.2ml), which is a third of the recommended 30 μg dose for people aged 12 years and older. A different, orange-capped vial will be used for paediatric doses.

The recommendations include:

  • all children aged 5-11 years should be vaccinated with paediatric Pfizer Covid 19 vaccine, children who have previously had Covid 19 can receive the paediatric dose after recovering from their illness or vaccination can be defered up to six months.
  • the schedule for vaccination in this age group is two doses, eight weeks apart - the interval can be shortened in special circumstances to a minimum of three weeks, such as in an outbreak response, prior to the initiation of significant immunosuppression or international travel
  • children who turn 12 after their first dose may receive the adolescent/adult formation of the Pfizer Covid 19 vaccine to complete their primary vaccine course
  • the paediatric vaccine can be coadministered with other vaccines

ATAGI has updated its recommendation for immunocompromised children aged 5-11 years can receive a third primary dose 2-4 months after their second dose.

Due to constant change about Covid 19 vaccination, for more information, please visit the following websites: